Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Phase I Study of RiMO-301 With Radiation in Advanced Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03444714
Recruitment Status : Recruiting
First Posted : February 23, 2018
Last Update Posted : January 5, 2022
University of Chicago
Information provided by (Responsible Party):
Coordination Pharmaceuticals, Inc.

Brief Summary:

This is a prospective, open-label, single arm, non-randomized study of RiMO-301 with radiation in patients with advanced tumors. A single escalation dose of RiMO-301 is intratumorally injected in a 3 + 3 study design to identify the recommended dose and dosing volumes.

Condition or Disease:

Patient with advanced tumor which is clinically accessible for intratumoral injection


Drug - RiMO-301

Radiation - Radiotherapy


Phase 1

Condition or disease Intervention/treatment Phase
Advanced Tumors Drug: RiMO-301 Phase 1

Detailed Description:

Primary Objectives:

• The primary objective is to determine the maximum tolerated dose (MTD) of RiMO-301 as determined by toxicity observed in patients treated with palliative radiation doses

Secondary Objectives:

  • To determine clinical response after RiMO-301 and radiotherapy as assessed by clinical response rate using clinical evaluation, imaging and/or symptom relief
  • To characterize adverse events of RiMO-301 in patients with advanced cancers
  • To evaluate the pharmacokinetics (PK) of RiMO-301 with radiation

The target population is patients with clinically accessible lesions for intratumoral injection. Up to 3 dose levels (5%, 10%, and 15% of the total baseline tumor volume, respectively) will be tested in a 3 + 3 dose escalation study design. MTD will be defined as the dose associated with a dose limiting toxicity (DLT) in less than or equal to 33% of patients at the dose level tested. Dose limiting toxicity (DLT) is defined as one of the following events occurring from the intratumor injection of RiMO-301 to 30 days after the completion of radiation treatment:

  • Grade 4 or greater treatment related hematologic or dermatologic toxicity
  • Any Grade 3 or greater treatment related non-hematologic, non-dermatologic toxicity (excluding nausea, vomiting or diarrhea without maximal medical intervention)

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 18 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: 3 + 3 dose escalation study design
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Dose-Escalating Study of RiMO-301 With Radiation in Advanced Tumors
Actual Study Start Date : April 10, 2018
Estimated Primary Completion Date : September 2022
Estimated Study Completion Date : December 2022

Arm Intervention/treatment
Experimental: RiMO-301+Radiotherapy
3 dose levels (5%, 10%, and 15% of the total baseline tumor volume, respectively) will be tested in a 3 + 3 dose escalation study
Drug: RiMO-301

Drug: RiMO-301 RiMO-301 will be administered by intratumoral route as slow injection

Radiotherapy Patients will receive 10 fractions of 3 Gy each over 2 weeks

Other Name: Radiotherapy

Primary Outcome Measures :
  1. Maximum Tolerated Dose (MTD) [ Time Frame: 45 days ]
    • To determine the maximum tolerated dose (MTD), which is defined as the dose level at which fewer than 33% of patients experience a dose limiting toxicity (DLT) using a 3+3 strategy

Secondary Outcome Measures :
  1. clinical benefit [ Time Frame: 45 days ]
    • To assess clinical benefit by change in tumor size and resolution of symptoms, which will be reported as response rate (%)

  2. adverse effect [ Time Frame: 45 days ]
    • To assess adverse effect as either treatment-related or non-treatment-related as defined by CTCAE

  3. Maximum Plasma Concentration [Cmax] [ Time Frame: 45 days ]
    • To evaluate Maximum Plasma Concentration [Cmax] of RiMO-301 in patients tested

  4. Area Under the Curve [AUC] [ Time Frame: 45 days ]
    To evaluate Area Under the Curve [AUC] of RiMO-301 in patients tested

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of advanced or metastatic cancer not amenable to curative therapy
  • Lesion that is amenable to palliative radiotherapy
  • Lesion that is technically feasible to irradiation and accessible for direct intratumoral injection
  • Target tumor in region not in previously irradiated field
  • Patient must have recovered from acute toxic effects (≤ grade 1) of previous cancer treatments prior to enrollment
  • Age >18 years
  • Has measurable disease, defined as at least 1 tumor that fulfills the criteria for a target lesion
  • Females with child bearing age should be using adequate contraceptive measures, should not be breast feeding and must have a negative pregnancy test prior to the start of dosing
  • Patients must sign a study-specific informed consent form prior to study entry

Exclusion Criteria:

  • Patients with a histological diagnosis of lymphomas and/or leukemias
  • Patients may not have received chemotherapy, targeted therapies, biologic response modifiers and/or hormonal therapy within the last 14 days
  • Ongoing clinically significant infection at or near the incident lesion
  • Major surgery over the target area (excluding placement of vascular access) <21 days from beginning of the study drug or minor surgical procedures <7 days
  • Other severe acute or chronic medical or psychiatric conditions or laboratory abnormality that would make the patient inappropriate for enrollment in this study
  • Has any mental or medical condition that prevents the patient from giving informed consent or participating in the trial
  • Pregnant and nursing women
  • Patients with a target lesion located in a previously irradiated field

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03444714

Layout table for location contacts
Contact: Ze-Qi Xu, Ph.D. 6304155601

Layout table for location information
United States, Illinois
University of Illinois at Chicago Recruiting
Chicago, Illinois, United States, 60612
Contact: Angelina Diaz    312-413-4262   
Principal Investigator: Lawrence Feldman, MD         
University of Chicago Medical Center Recruiting
Chicago, Illinois, United States, 60637
Contact: Robyn Hseu    773-834-3198   
Principal Investigator: Steven Steven Chmura, MD, Ph.D.         
Sponsors and Collaborators
Coordination Pharmaceuticals, Inc.
University of Chicago
Layout table for additonal information
Responsible Party: Coordination Pharmaceuticals, Inc. Identifier: NCT03444714    
Other Study ID Numbers: RiMO-CL17-001
First Posted: February 23, 2018    Key Record Dates
Last Update Posted: January 5, 2022
Last Verified: March 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: The data will not be shared due to confidentiality agreements

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Coordination Pharmaceuticals, Inc.: